Deerfield Management Company, L.P. (Series C) Cytek Biosciences, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 17,586 shares of CTKB stock, worth $112,374. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,586
Previous 155,759
88.71%
Holding current value
$112,374
Previous $869,000
88.84%
% of portfolio
0.0%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding CTKB
# of Institutions
134Shares Held
71.7MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$109 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$75.3 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$60.7 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$42.5 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$26.6 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $860M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...